liposomal bupivicaine (bupivacaine) (Pacira BioSciences)

Liposomal bupivacaine (marketed as Exparel) is an amide-type local anesthetic consisting of bupivacaine encapsulated within multivesicular liposomes using DepoFoam technology. This formulation is designed for single-dose administration to provide prolonged postsurgical analgesia by slowly releasing bupivacaine over an extended period, typically lasting up to 72 hours. It works by binding to voltage-gated sodium channels on the internal surface of nerve cell membranes, which inhibits the ionic fluxes required for the initiation and conduction of nerve impulses, thereby providing local anesthesia. Developed by Pacira BioSciences and FDA-approved since 2011, it is indicated for local infiltration and various peripheral nerve blocks (such as interscalene brachial plexus, sciatic, and adductor canal blocks) in both adults and pediatric patients aged 6 years and older to manage post-operative pain.

Brand names

Exparel

Other names

liposomal bupivacainebupivacaine liposomebupivacaine liposome injectable suspension